Evidence map›Paper›PMID 39160362›Full record

ArticleActa neuropathologica2024

Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases.

Frederique J Hart de Ruyter, Manon J A P Evers, Tjado H J Morrema, Anke A Dijkstra, Jurre den Haan, Jos W R Twisk, Johannes F de Boer, Philip Scheltens, Femke H Bouwman, Frank D Verbraak and 2 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Frederique J Hart de RuyterAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. f.hartderuijter@amsterdamumc.nl.ORCID 0000-0001-5023-4882
Manon J A P EversAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Tjado H J MorremaAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Anke A DijkstraAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Jurre den HaanAmsterdam UMC, Vrije Universiteit Amsterdam, Alzheimer Center Amsterdam, Neurology, De Boelelaan 1117, Amsterdam, The Netherlands.
Jos W R TwiskEpidemiology and Data Science, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Johannes F de BoerLaserLaB, Physics and Astronomy, Vrije Universiteit Amsterdam, De Boelelaan 1081, Amsterdam, The Netherlands.
Philip ScheltensAmsterdam UMC, Vrije Universiteit Amsterdam, Alzheimer Center Amsterdam, Neurology, De Boelelaan 1117, Amsterdam, The Netherlands.
Femke H BouwmanAmsterdam UMC, Vrije Universiteit Amsterdam, Alzheimer Center Amsterdam, Neurology, De Boelelaan 1117, Amsterdam, The Netherlands.
Frank D VerbraakAmsterdam UMC, Vrije Universiteit Amsterdam, Ophthalmology, De Boelelaan 1117, Amsterdam, The Netherlands.
Annemieke J RozemullerAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. jm.rozemuller@amsterdamumc.nl.
Jeroen J M HoozemansAmsterdam UMC, Vrije Universiteit Amsterdam, Pathology, Amsterdam Neuroscience, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Funding

Alzheimer Nederland AN-project WE.03-2021-14Netherlands Organisation for Scientific Research MEDPHOT P18-26 Project 5Netherlands Organisation for Scientific Research NWO
6 · The paper itself

Abstract

The retina is increasingly recognised as a potential source of biomarkers for neurodegenerative diseases. Hallmark protein aggregates in the retinal neuronal tissue could be imaged through light non-invasively. Post-mortem studies have already shown the presence of specific hallmark proteins in Alzheimer's disease, primary tauopathies, synucleinopathies and frontotemporal lobar degeneration. This study aims to assess proteinopathy in a post-mortem cohort with different neurodegenerative diseases and assess the presence of the primary pathology in the retina. Post-mortem eyes were collected in collaboration with the Netherlands Brain Bank from donors with Alzheimer's disease (n = 17), primary tauopathies (n = 8), synucleinopathies (n = 27), frontotemporal lobar degeneration (n = 8), mixed pathology (n = 11), other neurodegenerative diseases (n = 6), and cognitively normal controls (n = 25). Multiple cross sections of the retina and optic nerve tissue were immunostained using antibodies against pTau Ser202/Thr205 (AT8), amyloid-beta (4G8), alpha-synuclein (LB509), pTDP-43 Ser409/410 and p62-lck ligand (p62) and were assessed for the presence of aggregates and inclusions. pTau pathology was observed as a diffuse signal in Alzheimer's disease, primary tauopathies and controls with Alzheimer's disease neuropathological changes. Amyloid-beta was observed in the vessel wall and as cytoplasmic granular deposits in all groups. Alpha-synuclein pathology was observed as Lewy neurites in the retina in synucleinopathies associated with Lewy pathology and as oligodendroglial cytoplasmic inclusions in the optic nerve in multiple system atrophy. Anti-pTDP-43 generally showed typical neuronal cytoplasmic inclusion bodies in cases with frontotemporal lobar degeneration with TDP-43 and also in cases with later stages of limbic-associated TDP-43 encephalopathy. P62 showed inclusion bodies similar to those seen with anti-pTDP-43. Furthermore, pTau and alpha-synuclein pathology were significantly associated with increasing Braak stages for neurofibrillary tangles and Lewy bodies, respectively. Mixed pathology cases in this cohort consisted of cases (n = 6) with high Braak LB stages (> 4) and low or moderate AD pathology, high AD pathology (n = 1, Braak NFT 6, Thal phase 5) with moderate LB pathology, or a combination of low/moderate scores for different pathology scores in the brain (n = 4). There were no cases with advanced co-pathologies. In seven cases with Braak LB ≥ 4, LB pathology was observed in the retina, while tau pathology in the retina in the mixed pathology group (n = 11) could not be observed. From this study, we conclude that the retina reflects the presence of the major hallmark proteins associated with neurodegenerative diseases. Although low or moderate levels of copathology were found in the brains of most cases, the retina primarily manifested protein aggregates associated with the main neurodegenerative disease. These findings indicate that with appropriate retinal imaging techniques, retinal biomarkers have the potential to become highly accurate indicators for diagnosing the major neurodegenerative diseases of the brain.

Indexed as

Neurodegenerative DiseasesRetinatau ProteinsAgedAged, 80 and overalpha-SynucleinAlzheimer DiseaseAmyloid beta-PeptidesAutopsyDNA-Binding ProteinsFemaleHumansMaleMiddle AgedTauopathiesalpha-SynucleinAmyloid beta-PeptidesDNA-Binding ProteinsTARDBP protein, humantau ProteinsAlpha-synucleinAmyloid betaEye, retinaImmunohistochemistryNeurodegenerationNeuropathologyTauTDP-43

Identifiers

PMID39160362
PMCPMC11333524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.